1. Edvinsson L (2005) Clinical data on the CGRP antagonist BIBN4096BS for treatment of migraine attacks. CNS Drug Rev 11:69–76
2. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM, BIBN 4096 BS Clinical Proof of Concept Study Group (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110
3. Lipton RB, Coric V, Stock EG, Stock D, Morris BA, McCormack T, Frost M, Gentile K, Conway CM, Croop R (2018) Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a double-blind, randomized, placebo-controlled trial, Study 301. Poster PS123LB. Late breaking abstracts, American Headache Society 60th scientific meeting, San Francisco, CA, June 2018. Headache 58:1336–1337 (abstract)
4. Lipton RB, Coric V, Stock EG, Stock D, Morris BA, McCormack T, Frost M, Gentile K, Conway CM, Croop R (2018) Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a double-blind, randomized, placebo-controlled trial, Study 302. Poster IOR-02LB. Late breaking abstracts, American Headache Society 60th scientific meeting, San Francisco, CA, June 2018. Headache 58:1289 (abstract)
5. Lipton RB, Dodick DW, Ailani J, Lu K, Lakkis H, Finnegan M, Szegedi A, Trugman JM (2018) Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: results from a single attack phase III study, ACHIEVE II. Poster PS111B. Late breaking abstracts, American Headache Society 60th scientific meeting, San Francisco, CA, June 2018. Headache 58:1315–1316 (abstract)